-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MEDI-7352 in Diabetic Neuropathic Pain
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MEDI-7352 in Diabetic Neuropathic Pain Drug Details: MEDI-7352 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Benralizumab in Churg-Strauss Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Benralizumab in Churg-Strauss Syndrome Drug Details: Benralizumab (Fasenra) is a glyco-engineered monoclonal antibody, acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Benralizumab in Skin Rash
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Benralizumab in Skin Rash Drug Details: Benralizumab (Fasenra) is a glyco-engineered monoclonal antibody, acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Benralizumab in Rhinosinusitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Benralizumab in Rhinosinusitis Drug Details: Benralizumab (Fasenra) is a glyco-engineered monoclonal antibody, acts as an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Benralizumab in Hypereosinophilic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Benralizumab in Hypereosinophilic Syndrome Drug Details: Benralizumab (Fasenra) is a glyco-engineered monoclonal antibody, acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Non-Small Cell Lung Cancer Drug Details: MEDI-5752 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Renal Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Renal Cell Carcinoma Drug Details: MEDI-5752 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Gastric Cancer Drug Details: MEDI-5752 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Adenocarcinoma Of The Gastroesophageal Junction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: MEDI-5752 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Hepatocellular Carcinoma Drug Details: MEDI-5752 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MEDI-0618 in Migraine
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MEDI-0618 in Migraine Drug Details: MEDI-0618 is under development for the treatment of migraine. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MEDI-1341 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MEDI-1341 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drug Details:...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Runcaciguat in Non-Proliferative Diabetic Retinopathy (NPDR)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Runcaciguat in Non-Proliferative Diabetic Retinopathy (NPDR) Drug Details: Runcaciguat is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bentracimab in Bleeding And Clotting Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bentracimab in Bleeding And Clotting Disorders Drug Details: Bentracimab (PB-2452 (MEDI-2452)) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Suvratoxumab in Ventilator Associated Pneumonia (VAP)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Suvratoxumab in Ventilator Associated Pneumonia (VAP) Drug Details: Suvratoxumab (MEDI-4893) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Suvratoxumab in Staphylococcus aureus Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Suvratoxumab in Staphylococcus aureus Infections Drug Details:Suvratoxumab (MEDI-4893) is under development for the prevention of ventilator...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Daxdilimab in Systemic Lupus Erythematosus
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Daxdilimab in Systemic Lupus Erythematosus Drug Details: Daxdilimab (VIB-7734, MEDI-7734) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tozorakimab in Acute Respiratory Failure
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tozorakimab in Acute Respiratory FailureDrug Details: Tozorakimab (MEDI-3506) is under development for the treatment of diabetic kidney...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dazodalibep in Kidney Transplant Rejection
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dazodalibep in Kidney Transplant Rejection Drug Details: Dazodalibep (VIB-4920, MEDI-4920) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tozorakimab in Asthma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tozorakimab in Asthma Drug Details: Tozorakimab (MEDI-3506) is under development for the treatment of diabetic kidney disease,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.